3.时间要求：2025年内正式发表的研究成果（2025年1月1日至2025年12月31日）。

中国营养学会肥胖防控分会和西安交通大学全球健康研究院等机构合作，在2025年3月4日“世界肥胖日” 发布了“2024年中国肥胖研究十大成果”评选活动，旨在助力推动未来我国肥胖防控工作，总结2024年我国肥胖研究的重要突破、引领未来肥胖防控相关研究的方向，促进社会大众对肥胖防控重要性的认知，并促成肥胖研究领域的合作。

该项目通过成果汇总-初步筛选-再次筛选-专家遴选-专家讨论等5个环节，评出了2024年度中国肥胖研究十大成果，成果包括3项临床试验、2项机制研究、2项观察性研究以及3项综述/指南，如下（排名无先后）。

1. Lancet Diabetes Endocrinology：母义明（中国人民解放军总医院）团队发表 Efficacy and safety of once weekly semaglutide 2.4 mg for weight management in a predominantly east Asian population with overweight or obesity（STEP 7）: a double-blind, multicentre, randomised controlled trial（STEP 7）; a double-blind multicentre randomised controlled trial^[1]

2. JAMA：李小英（复旦大学附属中山医院）团队发表 Tirzepatide for weight reduction in Chinese adults with obesity: the SURMOUNT-CN randomized clinical trial^[2]

3. Cell Reports Medicine：刘刚（华中科技大学公共卫生学院）团队发表 Effects of healthy low-carbohydrate diet and time-restricted eating on weight and gut microbiome in adults with overweight or obesity: feeding RCT^[3]

4. Cell Metabolism：王福俤（浙江大学）团队发表 Adipocyte-derived ferroptotic signaling mitigates obesity^[4]

5. Cell Metabolism：强力（北京大学）团队发表 FcRn-dependent IgG accumulation in adipose tissue unmasks obesity pathophysiology^[5]

6. Lancet Public Health：宋逸（北京大学）、董彦会（北京大学）团队发表 Trends and inequalities in thinness and obesity among Chinese children and adolescents: evidence from seven national school surveys between 1985 and 2019^[6]

7. EClinicalMedicine：牟建军（西安交通大学）团队发表 The association of long-term trajectories of BMI, its variability, and metabolic syndrome: a 30-year prospective cohort study^[7]

8. 中华消化外科杂志：国家卫生健康委员会医政司发表肥胖症诊疗指南（2024 年版）^[8]

9. 中国预防医学杂志：中国营养学会肥胖防控分会等发表中国居民运动减重专家共识^[9]

10. Lancet：李舍予（四川大学华西医院）团队发表 Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta–analysis of randomised controlled trials^[10]

2024年，中国科学家在肥胖研究领域取得了丰硕的成果，为肥胖防控做出了重要贡献。这些研究覆盖肥胖的相关机制、肥胖的流行趋势、肥胖的健康结局、肥胖的复杂危险因素、临床治疗和预防措施等。此次评选出的成果只是这些重要研究的部分代表。再次祝贺入选的10大成果研究团队，致敬我国肥胖领域全部专家们的贡献！

参考文献：

[1] MU Y, BAO X, ELIASCHEWITZ F G, et al. Efficacy and safety of once weekly semaglutide 2·4 mg for weight management in a predominantly east Asian population with overweight or obesity (STEP 7): a double-blind, multicentre, randomised controlled trial [J]. Lancet Diabetes Endocrinol, 2024, 12(3): 184-95.DOI:10.1016/s2213-8587(23)00388-1

[2] ZHAO L, CHENG Z, LU Y, et al. Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial [J]. Jama, 2024, 332(7): 551-60.DOI:10.1001/jama.2024.9217

[3] LI L, LI R, TIAN Q, et al. Effects of healthy low-carbohydrate diet and time-restricted eating on weight and gut microbiome in adults with overweight or obesity: Feeding RCT [J]. Cell Rep Med, 2024, 5(11): 101801.DOI:10.1016/j.xcrm.2024.101801

[4] WANG X, WU Q, ZHONG M, et al. Adipocyte-derived ferroptotic signaling mitigates obesity [J]. Cell Metab, 2025, 37(3): 673-91.e7.DOI:10.1016/j.cmet.2024.11.010

[5] YU L, YANG Y X, GONG Z, et al. FcRn-dependent IgG accumulation in adipose tissue unmasks obesity pathophysiology [J]. Cell Metab, 2025, 37(3): 656-72.e7.DOI:10.1016/j.cmet.2024.11.001

[6] SONG X, ZHOU B, BAIRD S, et al. Trends and inequalities in thinness and obesity among Chinese children and adolescents: evidence from seven national school surveys between 1985 and 2019 [J]. Lancet Public Health, 2024, 9(12): e1025-e36.DOI:10.1016/s2468-2667(24)00211-1

[7] GUO T, ZHENG S, CHEN T, et al. The association of long-term trajectories of BMI, its variability, and metabolic syndrome: a 30-year prospective cohort study [J]. EClinicalMedicine, 2024, 69: 102486.DOI:10.1016/j.eclinm.2024.102486

[8] 中华人民共和国国家卫生健康委员会医政司. 肥胖症诊疗指南（2024年版）[J].2024,23(10):1237-60.

[9] 孙晓敏，车碧众，苟波，等. 中国居民运动减重专家共识[J].中国预防医学杂志,2024,25(04):395-405.

[10] SHI Q, WANG Y, HAO Q, et al. Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials [J]. Lancet, 2024, 403(10434): e21-e31.DOI:10.1016/s0140-6736(24)00351-9